Lisa A Cannon Albright

Title: Lisa A Cannon Albright: Innovator in Human Genetics

Introduction

Lisa A Cannon Albright is a prominent inventor based in Salt Lake City, UT (US). She has made significant contributions to the field of human genetics, particularly in the area of prostate cancer susceptibility. Her work has implications for diagnosis, prognosis, and therapy in cancer treatment.

Latest Patents

Lisa A Cannon Albright holds a patent for the invention titled "Chromosome 17P-linked prostate cancer susceptibility gene." This invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2). The patent addresses germline mutations in the HPC2 gene and their use in diagnosing predisposition to prostate cancer. It also discusses presymptomatic therapy for individuals carrying deleterious alleles of the HPC2 gene. Furthermore, the invention explores somatic mutations in the HPC2 gene in human prostate cancer and their diagnostic and prognostic applications. The invention also covers therapies for human cancers with mutations in the HPC2 gene, including gene therapy and drug screening.

Career Highlights

Throughout her career, Lisa has worked with notable organizations such as Myriad Genetics, Inc. and the University of Utah Research Foundation. Her expertise in genetics has positioned her as a key figure in cancer research and therapy development.

Collaborations

Lisa has collaborated with esteemed colleagues, including Sean V Tavtigian and David H-f Teng. These partnerships have furthered her research and contributed to advancements in the understanding of cancer genetics.

Conclusion

Lisa A Cannon Albright's innovative work in human genetics, particularly regarding prostate cancer susceptibility, showcases her dedication to advancing medical science. Her contributions have the potential to improve diagnosis and treatment options for individuals at risk of cancer.